Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 1014 • 2012 ACR/ARHP Annual Meeting
Trimmed Analyses, a New Approach to the Analysis of Sharp Score Data in the Assessment of Progression in Patients with Rheumatoid Arthritis
Robert B. M. Landewé¹, Désirée van der Heijde², Carol Connell³, John Bradley⁴, David Gruben³ and Michael Brown³, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the Phase 3 ORAL…
Abstract Number: 2489 • 2012 ACR/ARHP Annual Meeting
Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634
Frédéric Vanhoutte¹, Minodora Mazur², Annegret Van der Aa¹, Piet Wigerinck¹ and Gerben van 't Klooster¹, ¹Galapagos NV, Mechelen, Belgium, ²Rheumatology, State Medical and Pharmaceutical University "Nicolae Testemitanu", Chisinau, Moldova
Background/Purpose: Janus kinases (JAKs) are critical components in signaling pathways for a number of cytokines and growth factors, including those involved in the disease process…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting
STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis
Jehad H. Edwan¹, Tri M. Tran², Mones Abu-Asab³, Raphaela T. Goldbach-Mansky⁴ and Robert A. Colbert¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³NEI NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
S. Cohen¹, S. Krishnaswami², B. Benda³, R. Riese², M.G. Boy⁴, D. Gruben⁴, G. Wallenstein⁵, C. A. Mebus⁴, S. H. Zwillich² and J. D. Bradley⁶, ¹Metroplex Clinical Research Centre, Dallas, TX, ²Pfizer Inc., Groton, CT, ³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…
Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting
Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Ronald J. Hill¹, Angelina Bisconte¹, J. Michael Bradshaw¹, Ken Brameld², Eun Ok Kim¹, Xiaoyan Li², Tim Owens², Erik Verner² and David M. Goldstein², ¹Biology, Principia Biopharma, South San Francisco, CA, ²Chemistry, Principia Biopharma
Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…
Abstract Number: 2150 • 2012 ACR/ARHP Annual Meeting
Action of Tofacitinib Via Human Dendritic Cells
Satoshi Kubo¹, Kunihiro Yamaoka², Shigeru Iwata¹ and Yoshiya Tanaka¹, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has gathered attention in treatment of Rheumatoid arthritis (RA). Although JAKs are well known for its importance…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.